103 related articles for article (PubMed ID: 24164299)
1. Routine histopathologic characteristics can predict oncotype DX(TM) recurrence score in subsets of breast cancer patients.
Mattes MD; Mann JM; Ashamalla H; Tejwani A
Cancer Invest; 2013 Nov; 31(9):604-6. PubMed ID: 24164299
[TBL] [Abstract][Full Text] [Related]
2. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
[TBL] [Abstract][Full Text] [Related]
5. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
6. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
8. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
9. High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.
Ly M; Antoine M; Dembélé AK; Levy P; Rodenas A; Touré BA; Badiaga Y; Dembélé BK; Bagayogo DC; Diallo YL; Koné AA; Callard P; Bernaudin JF; Diallo DA
Oncology; 2012; 83(5):257-63. PubMed ID: 22964749
[TBL] [Abstract][Full Text] [Related]
10. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
11. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
12. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
13. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score.
Gwin K; Pinto M; Tavassoli FA
Int J Surg Pathol; 2009 Aug; 17(4):303-10. PubMed ID: 19578051
[TBL] [Abstract][Full Text] [Related]
14. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
Wolf I; Ben-Baruch N; Shapira-Frommer R; Rizel S; Goldberg H; Yaal-Hahoshen N; Klein B; Geffen DB; Kaufman B
Cancer; 2008 Feb; 112(4):731-6. PubMed ID: 18076012
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.
Acs G; Kiluk J; Loftus L; Laronga C
Mod Pathol; 2013 Nov; 26(11):1451-60. PubMed ID: 23743933
[TBL] [Abstract][Full Text] [Related]
16. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Lee JJ; Shen J
Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
[TBL] [Abstract][Full Text] [Related]
17. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
18. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
[TBL] [Abstract][Full Text] [Related]
19. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
Geradts J; Bean SM; Bentley RC; Barry WT
Cancer Invest; 2010 Nov; 28(9):969-77. PubMed ID: 20873988
[TBL] [Abstract][Full Text] [Related]
20. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
